Harmony Biosciences Holdings, Inc.
HRMY
NASDAQ
Healthcare
$37.26
+3.50%gain today
Market position
Market cap rank
#2038
of 2,614
1-day
+3.50%
1-month
+20.54%
6-month
-0.43%
YTD
-0.32%
1-year
+16.04%
5-year
+28.57%
Key figures
Market cap
$2.16B
P/E (live)
13.5
price ÷ annual EPS
P/E (reported)
13.6
FY 2025
EPS
$2.76
FY 2025
Dividend yield
0.00%
FY 2025
Dividend / share
$0.00
Gross margin
77.16%
FY 2025
Operating margin
24.00%
FY 2025
Net margin
18.27%
FY 2025
Return on equity
—
FY 2025
Valuation & financial health
Enterprise value
$1.64B
FY 2025
EV / EBITDA
6.42
FY 2025
EV / Sales
1.89
FY 2025
Price / book
2.47
FY 2025
Price / sales
2.48
FY 2025
Earnings yield
7.38%
FY 2025
FCF yield
16.17%
FY 2025
Debt / equity
0.28
FY 2025
Current ratio
3.60
FY 2025
Return on assets
—
FY 2025
Return on invested capital
Financials · FY 2025
Revenue
$868.45M
Gross profit
$670.11M
Operating income
$208.47M
EBITDA
$255.05M
Net income
$158.69M
Diluted EPS
$2.71
Shares outstanding
57,492,277
Trading
Open
$35.99
Previous close
$36.00
Day range
$35.92 – $37.38
52-week range
$25.52 – $40.87
50-day avg
$32.46
200-day avg
$32.32
Volume
1,012,967
Avg volume
842,143
Beta
0.97
Price history
+16.04% over 1Y
Compare with peers
About Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
Visit websiteCompany info
CEO
Jeffrey Dayno
IPO date
Aug 19, 2020
Headquarters
Plymouth Meeting, PA, US
Country
Fundamentals are annual. Figures labeled with their fiscal year.
